Cancer And The Immune System: FDA Panel’s Approval Of Pioneering T-Cell Therapy

Print icon

The future of cancer care is increasingly driven by advances in immunotherapy and genomics, as shown by the latest treatment recommended for approval July 12 by an FDA advisory committee for certain patients with leukemia.

The pioneering T-cell therapy, created at the University of Pennsylvania and licensed to the pharmaceutical company Novartis, involves removing immune cells from the patient’s bloodstream, genetically reengineering them to recognize and kill cancer, multiplying the immune cells and infusing them into the patient’s body.

The advisory committee recommended the therapy for patients ages 3 to 25 with B-cell acute lymphoblastic leukemia that has relapsed or has not responded to standard treatments. The FDA is expected to announce its decision on making the protocol available in the next few months.

“This is an exciting advance that has, and will, save lives,” says Peter Yu, physician-in-chief of the Hartford HealthCare Cancer Institute. “It has been developed over the last four to five years and is part of the growing story of immunotherapy and cancer. We have learned that the immune system has so many weapons at its disposal.”

Yu expects the FDA will approve use of the immunotherapy in a limited number of sites across the United States, which should include the Memorial Sloan Kettering Cancer Center, an HHC partner.

“We anticipate our patients who need this therapy will have access to it at Memorial Sloan Kettering,” he says, through highly specialized resources and “exquisite coordination” with Hartford HealthCare physicians.

Besides this new T-cell therapy being developed, other research studies into perfecting and implementing genetic therapy for cancer patients are ongoing, including a Memorial Sloan Kettering study that HHC patients can join right here in Connecticut at the HHC Cancer Institute.

While Dr. Yu says “for the right patient, this treatment is going to be life changing and life saving,” the anticipated initial approval of T-cell therapy will be for use in patients whose disease has not been controlled by earlier treatments with conventional therapies, by which time the patient is often weaker and the disease harder to treat.

“They’re looking at the timing of its use – whether we can give it sooner so the patients have fewer side effects and it might be more effective,” he says of the T-cell therapy.

Earlier use may also help patients avoid such difficult treatments as bone marrow transplants.

Other studies are investigating the application of this new treatment to cancers such as leukemia not borne in the bloodstream. Approximately 90 percent of patients have so-called “solid tumors” of the lungs, ovaries or other organs. Dr. Yu says immunotherapy with reengineered T-cells may not be as effective in these cases because they may be less able to kill tumors when required to leave the bloodstream and locate their targets in other parts of the body.

“The question is, Can these reengineered cells get into solid tumors?” says Dr. Yu. “Perhaps there are other kinds of immune cells that may be better subjects for genetic engineering to accomplish this.”

But in some cases, T-cell therapy may be more effective than chemotherapy. The treatment holds promise for use against glioblastoma, the aggressive type of brain cancer afflicting Sen. John McCain, says Dr. Yu. The brain typically has been a challenge for standard cancer treatments, but T-cell therapy may prove effective because immune cells are better able to enter the brain than chemotherapy drugs, which need to get through the blood-brain barrier that protects the brain from many drugs.

In the meantime, some area leukemia patients at the Cancer Institute locations may soon be referred to Memorial Sloan Kettering to access the advanced, newly-approved therapy.

“T-cell therapy represents a continuation of the renaissance of blood and cancer care,” says Dr. Jeffrey Gordon, an oncologist with Hartford HealthCare Medical Group Oncology. “For my patients who may need this type of therapy, the relationship that Hartford HealthCare has with the Memorial Sloan Kettering Cancer Center opens up a door of opportunity for them. They can get the most up-to-date, technologically advanced therapy while still being connected to their care close to home.”

For more information on the Hartford HealthCare Cancer Institute, click here.

 


What's New


Baby Boomers, Beware: You Are At Risk For Hepatitis C.

More than 3 million people live with hepatitis C, the most common blood-borne disease affecting the baby boomer generation – but many don’t even know they have it. Hartford Hospital‘s Dr. Michael Einstein tells you what you need to know about this devastating liver disease: Q: Who is at risk for...


New Melanoma Center Offers ABC’s of Skin Cancer

We love our beach days and warm sunshine, but the sobering fact is that there are more new cases of skin cancer in this country each year than breast, prostate, lung and colon cancer combined. “At particular risk are people with pale skin or who have a family history of...


Back-To-School Sports: Hydration and Concussions

By Bill LaBruna With back-to-school around the corner, it’s important to be aware of your young athlete’s health on and off the field. Hydration Hydration is crucial to good overall health and athletic performance. Dehydration affects their performance and also puts them at risk for fatigue, nausea, heat cramps or,...